1 billion 122 million! Junzheng group strides into the field of blood products

[pharmaceutical network enterprise news] on February 18, 2020, Junzheng group announced that Lhasa Shengtai, a wholly-owned holding company of the company, planned to subscribe RMB 1.122 billion for an additional contribution of RMB 357 million from Da'an pharmaceutical, a related party, accounting for 31.17% of the registered capital after the capital increase and share expansion of Da'an pharmaceutical Among them, it is worth noting that Junzheng group's main business is the production and sales of chemical products, while Da'an pharmaceutical is mainly engaged in the production and sales of blood products, with great differences between the two industries Therefore, the capital increase of Junzheng group to Da'an pharmaceutical is a cross industry investment It is understood that blood products are the plasma protein components prepared by healthy human plasma or specific immune human plasma, by separation, purification or recombinant DNA technology, as well as the general name of the tangible components of blood cells, mainly including albumin, immunoglobulin, coagulation factor, anticoagulant blood protein and protease inhibitor, etc The international society for plasma protein therapy (PPTA) has pointed out that blood products are a special kind of biological products It plays an irreplaceable role in clinical first aid, disease prevention and treatment In terms of the current structure, albumin dominates the domestic market, with the low proportion of jing-c and factor products, so there is a large space for improvement in the future In the past 17 years, the albumin market in the domestic blood product market was about 13 billion yuan, accounting for 62%, dominating the domestic blood product market, with the proportion of intravenous injection and propofol accounting for 19%, and the proportion of coagulation factors accounting for 8%, accounting for a relatively low proportion Compared with the mature foreign market, there is a large room for improvement in the future Novel coronavirus pneumonia is a major drug that has been used in the field The main reason for this is that the new crown pneumonia epidemic has not yet been effective, and it mainly relies on its own immunity to resist the virus However, one of the treatment methods is injecting intravenous immunoglobulin, namely static C Jingbing contains broad-spectrum antibodies, which can enhance immunity and prevent viral infection It has an irreplaceable role in the fight against this epidemic Previously, Beijing Union Medical College Hospital's proposal for the diagnosis and treatment of new coronal lung indicated that severe patients should use IVIG as early as possible It is reported that affected by this, the related blood product plates have been surging, such as the word board of Shanghai Laishi and Tiantan biology, Boya biology, Hualan biology, Shuanglin biology, Weiguang biology and so on Of course, in addition to the impact of the epidemic, the market of blood products has been expanding in recent years According to some data, the domestic blood product market increased from 8.5 billion yuan in 2010 to about 23 billion yuan in 2018, with a compound growth rate of 15.3% It is estimated that the domestic blood product industry will exceed 40 billion yuan in 2024 As blood products have both resource attribute and policy barrier resource attribute, and in recent years, the national new batch pulp station has become increasingly strict Under the increasingly obvious scale effect of blood products, the industry is expected to significantly increase the industry concentration in the future, and is not easily affected by volume procurement On the whole, after the future epidemic, the supply and demand of blood products may change greatly The shortage of blood products to some extent will lead to the rise of prices In addition, due to the foundation of academic promotion, the cost side will be further reduced, which will lead to the continuous improvement of the profitability of blood products enterprises